All Artificial Intelligence & Computational Tools articles
-
NewsMathematical model probes metals’ role in Alzheimer’s plaque formation
A mathematical framework simulates how metals such as copper and zinc interact with amyloid-beta, offering a new computational tool to explore plaque formation and potential therapeutic interventions in Alzheimer’s disease.
-
ArticleAI agents vs scientists: what should we automate in drug discovery?
AI agents can search, analyse and plan across drug discovery workflows, but where should scientists hand over control? We examine what to automate, what to check and where human judgement matters most.
-
ArticleWhy AI struggles with new drug targets – and how physics could help
Virtual screening can assess billions of compounds, but performance can fall on unfamiliar targets. Combining AI with molecular physics could help make predictions more reliable.
-
NewsInsilico Medicine launches open-source AI longevity research toolkit
Insilico Medicine has published a Cell cover study introducing LongevityBench, a suite of specialised AI models and an autonomous agentic discovery platform.
-
NewsMicroproteins emerge as potential new Alzheimer’s targets
Scientists at the Salk Institute have constructed a comprehensive atlas of previously uncharacterised microproteins in the human frontal cortex, identifying over 1,000 novel candidates.
-
ArticleFast-tracking AI-designed binders with cell-free expression and SPR
AI can rapidly generate new protein binders, but wet-lab validation remains a major bottleneck. Combining cell-free protein synthesis with surface plasmon resonance (SPR) enables AI-designed antibody binders to be screened directly from crude extracts, bypassing lengthy cell culture and purification steps.
-
NewsOutSee secures £50k innovate UK grant for AI target validation
UK genomics and drug discovery company OutSee has received £50,000 in Innovate UK funding to develop an agentic AI sub-system designed to automate the initial triage of drug targets identified by its Nomaly genomics engine.
-
ArticleSix assay requirements every researcher using NAMs should know
As NAMs become more widely used in drug discovery, assays must meet the demands of more complex models. Discover six requirements for reliable, reproducible and biologically meaningful data.
-
ArticleHow AI-driven systems biology will reset the starting line for drug development
AI is making drug discovery faster, but can it make it more successful? Discover why combining AI with systems biology could help researchers tackle the biological complexity behind drug failure.
-
ArticleWhy intracellular targets remain a major drug discovery challenge – and how they’re becoming druggable
Many biologically important intracellular targets remain difficult to drug. Dr Rab Prinjha examines how screening within living cells could help tackle them.
-
ArticleReducing drug development failures with human-relevant models and AI
Professor Joseph C. Wu of Stanford University explains how stem cells, human-relevant models and AI are helping researchers predict which drug candidates are most likely to succeed before clinical trials.
-
NewsAI designs functional bacteriophage genomes to overcome bacterial resistance
Scientists have used artificial intelligence to design complete, functional bacteriophage genomes from scratch, with engineered phages capable of overcoming resistance in bacteria that had defeated naturally occurring viruses — marking a significant step towards AI-driven whole-genome engineering.
-
ArticleWhy single-cell foundation models have underdelivered and what drug discovery needs instead
Foundation models have delivered breakthroughs in protein biology, but single-cell models have struggled to match them. What is holding them back?
-
NewsAI and genetics identify WNK2 inhibitor for osteoarthritis treatment
Researchers at University of Utah Health have used artificial intelligence and human genetic data to identify a promising early-stage drug candidate targeting WNK2, a protein linked to inherited osteoarthritis, with the lead compound reducing inflammatory gene activity and supporting cartilage cell health in laboratory models.
-
NewsWhat Google’s AI talent exodus could mean for future drug discovery
The departure of leading AI researchers from Google to found Discovery Loop raises important questions about the future direction of artificial intelligence in scientific research and drug development.
-
NewsGlymphatic gene therapy platform targets brain’s glial cells precisely
A new gene therapy platform exploiting the brain’s glymphatic transport system and engineered AAV5 vectors could offer a targeted treatment route for multiple sclerosis, Huntington’s disease and rare white matter disorders.
-
NewsInsilico Medicine launches AI drug discovery benchmarking platform
Insilico Medicine has unveiled a benchmarking platform designed to assess whether AI models can perform genuine drug discovery tasks, using decontaminated real-world datasets and proprietary validated programmes to move beyond inflated benchmark scores.
-
ArticleAI’s promise and practical limits in drug discovery
From ChatGPT to AI agents and world models, where is AI really heading in drug discovery? Dr Raminderpal Singh explains what researchers should focus on now.
-
News3D genome reorganisation identified as Alzheimer’s disease molecular hallmark
An international study combining single-cell genomics, spatial transcriptomics and artificial intelligence has identified large-scale changes in three-dimensional genome organisation in Alzheimer’s-affected brain cells, establishing chromatin architecture as a previously overlooked component of the disease’s molecular pathology and a potential framework for future therapeutic targeting.
-
ArticleMaking historical toxicology data work harder in safety assessment
Historical toxicology data is often underused. Find out how Virtual Control Groups and AI could help researchers strengthen safety assessment while making better use of existing data.